Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q4 2023 Earnings Call Transcript

Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q4 2023 Earnings Call Transcript March 28, 2024

Helius Medical Technologies, Inc. beats earnings expectations. Reported EPS is $-1.47, expectations were $-4.05. HSDT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: Good day, and thank you for standing by, and welcome to Helius Medical Technologies, Inc. Q4 2023 Earnings Conference Call. At this time all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your speaker today, Michelle Bilski, In-Site Communications. Please go ahead.

Michelle Bilski: Thank you, operator. Welcome to the fourth quarter 2023 earnings conference call for Helius Medical Technologies. This is Michelle Bilski of In-Site Communications, Investor Relations for Helius. With me on today’s call are Dane Andreeff, Helius Medical’s President and Chief Executive Officer; and Jeff Mathiesen, Chief Financial Officer. At this time all participants have been placed in a listen-only mode. Please note that this call is being recorded and access to the webcast can be obtained through the Investors section of the Helius website at www.heliusmedical.com. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management.

These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those indicating, including those identified in the Risk Factors section of our most recent annual report on Form 10-K. Such factors may be updated from time to time in our other filings with the SEC, which are available on our website. All statements made during this call are as of March 28, 2024. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law. I would now like to turn the call over to Dane Andreeff, President and Chief Executive Officer of Helius.

Dane Andreeff: Thanks, Michelle, and thank you to everyone joining us today on Helius Medical’s fourth quarter 2023 and earnings conference call. I’m happy to report that during 2023 and over the past few months, we’ve taken several meaningful steps towards two important milestones in the United States, achieving widespread reimbursement for PoNS and FDA approval for stroke. I’ll start with our pursuit of broad reimbursement for PoNS. As you know, PoNS is currently authorized in the United States to treat gait deficit due to mild-to-moderate symptoms from MS. We are thrilled that CMS recently assigned us unique HCPCS codes for both PoNS controller and the PoNS mouthpiece effective April 1st, 2024. These codes allow us to begin negotiating reimbursement with third-party payers and gives us the option to submit claims on a case-by-case basis.

We now expect to engage with CMS in the coming weeks and at the public meeting this summer with the objective of securing Medicare reimbursement for the PoNS controller and mouthpiece in their next cycle. If we are successful, reimbursement will be effective October 1st, 2024. To further support our reimbursement efforts, we anticipate getting primary endpoint data from PoNS step during the third quarter with preliminary study results communication before year-end. As a reminder, PoNS step is a company-sponsored research trial designed to evaluate the impact of MS patient adherence to PoNS Therapy in a real-world clinical setting. We expect data from this program to underscore the effectiveness of PoNS in treating gait imbalance impairment as well as its long-term therapeutic benefit.

Recently, we initiated efforts to target the Department of Veterans Affairs through their nationwide multiple sclerosis centers of excellence, the VA provides healthcare services to veterans with MS from the time of diagnosis and through the rest of their lives, and more than 28,000 cases are reported to the VA annually, fact to establish a partnership with an authorized supplier to the VA in the near future. Now on to the achievements we made towards our goal of securing U.S. commercial authorization for stroke. In the U.S., over 5 million stroke survivors are affected by walking and balanced disability and falling is a prevailing concern for stroke survivors. Clinical evidence out of Canada shows that patients treated with PoNS Therapy see substantial improvement in gait imbalance.

Furthermore, in the real-world database analysis, the majority of the patients before starting PoNS Therapy were at risk of falling. While routine rehabilitation physical therapy provides about a 1% to 3% reduction in risk remarkably after 14 weeks of treatment with PoNS Therapy, 28% of the patients were no longer at fall risk. This is a clinically meaningful and impactful improvement. Fall related events are dangerous to the patient, resulting in additional injuries and new or lengthened hospital stays, which presents a significant financial burden to the healthcare system with the average treatment cost per fall estimated at $64,500. If you compare that to the number to our list price of PoNS system at $25,700, the health economic equation greatly favors the use of PoNS.

With PoNS Therapy, we have a huge opportunity to improve the lives of patients suffering from stroke will also helping to reduce the considerable fall-related economic burden to providers, which totals an estimated of $50 billion per year. In Canada, where PoNS is already authorized for stroke, the government and providers are already starting to see the clinical and economic benefit of PoNS. Early in the fourth quarter, we received a letter of intent from the Quebec Ministry of Health and Social Services to purchase 30 PoNS devices. We are currently working to establish five sites in five separate administrative regions as part of a government-funded initiative designed to further validate the effectiveness of PoNS Therapy when used by patients suffering the effects of stroke.

We believe this program will not only accelerate adoption in Canada, but will also increase the body of therapeutic evidence toward our pursuit of market access and third-party coverage here in the United States. Also critical to achieving market access is our ongoing investigator-initiated placebo-controlled study by Dr. Steven Kautz at the Medical University of South Carolina, which evaluates the effects of cranial nerve, non-invasive neuromodulation delivered using PoNS Therapy on gait and dynamic balance in chronic stroke survivors. We also began an open-label study as part of our registrational program, raising the total number of participants between the two studies to approximately 100. In January, Brooks Rehabilitation Hospital joined the program as a second site to Dr. Kautz’s study and is now also the first site to have start enrolling patients in the open-label study.

We believe that bringing PoNS clinical experience to additional sites in the U.S. through the open-label study will further support our stroke authorization efforts. We also recently aligned with the FDA on our stroke development plan. Through this plan, we could leverage the randomized controlled study at MUSC as part of the registrational program, along with the open-label study and real-world evidence from Canada to significantly streamline the size, time line in the cost of the registrational program. A more efficient path to approval is great news, not only for Helius, but also for the millions of stroke survivors in the U.S., who could benefit from PoNS Therapy. We are targeting regulatory submission by early 2025 with the goal of receiving marketing authorization utilizing PoNS breakthrough designation in stroke later in the same year.

If authorized to treat stroke in the U.S., PoNS would be eligible for the proposed Transitional Coverage of Emerging Technologies, or TCET pathway, which would expedite Medicare coverage of certain breakthrough – certain breakthrough devices and allow for temporary coverage within six months after FDA market authorization. An estimated 90% of stroke patients in the U.S. are covered by Medicare. Turning now to our Canadian activities. Early in the fourth quarter, Pacific Blue Cross and HealthTech Connex published a white paper demonstrating PoNS Therapy can drastically improve return-to-work outcomes for patients suffering from traumatic brain injury, or TBI. The program participants included patients that at least two years post injury, who did not respond to standard rehabilitation treatments and were not expected to return-to-work.

After 14 weeks of PoNS Therapy, 89% of the study participants said that balancing gait was no longer a barrier to work. 56% return-to-work, and 80% of those who returned were able to work full time at their prior occupations for at least six months. As you can imagine, these were incredibly gratifying results. PoNS Therapy is truly a game-changer for people suffering from gaining balance impairment, and we are optimistic that the findings from this white paper will advance our efforts to gain reimbursement by Canadian insurance companies and health care providers as well as demonstrating PoNS significant health economic benefit and cost-effectiveness as we negotiate coverage with U.S. payers. As you’ve heard today, we see several upcoming milestones on the path ahead and expect 2024 to be another year of marching steadily toward our goals.

With $1.3 million raised under our ATM program since year-end, our cash runway has been extended into the third quarter of this year, allowing us to continue pursuing widespread reimbursement while making progress on stroke. With that, let me turn the call over to Jeff to discuss our fourth quarter financial results in detail.

Jeff Mathiesen: Thanks, Dane. It is a pleasure to be with you today. Total revenue for the fourth quarter of 2023 was $134,000 compared to $282,000 in the fourth quarter of 2022. The decrease was primarily attributable to the June 30, 2023 expiration of the PTAP program in the United States, along with lower Canadian product sales. For the fourth quarter of 2023, cost of revenue was $90,000 compared to $150,000 for the prior year period, with the decrease primarily due to decreased revenues in the current year. Selling, general and administrative expense for the fourth quarter of 2023 was $1.6 million, a decrease of $0.4 million compared to $2 million in the fourth quarter of 2022, primarily due to a decrease in compensation-related expenses.

Cash and – research and development expenses for the fourth quarter of 2023 were $0.7 million compared to $0.8 million in the fourth quarter of 2022, resulting primarily from a decrease in clinical and product development expenses in the current year. Operating loss for the fourth quarter of 2023 decreased to a loss of $2.2 million compared to an operating loss of $2.7 million in the fourth quarter of 2022. Net loss was $1 million for the fourth quarter of 2023 compared to a net loss of $4.9 million in the fourth quarter of 2022. The basic and diluted net loss per share for the fourth quarter of 2023 was $1.47 compared to a net loss per share of $8.66 in the fourth quarter of 2022. Our cash burn from operations in the fourth quarter of 2023 was $2 million compared to $2.1 million in the fourth quarter of 2022.

As of December 31, 2023, we had $5.2 million in cash and no debt. As Dane mentioned, we generated $1.3 million of net proceeds from the sale of shares of our common stock under our ATM program since the end of the year, sold at an average share price of $9.27 per share, which extends our cash runway into the third quarter of 2024. In closing, PoNS sales are currently on a cash pay basis and as a price point that is not feasible for a vast majority of the patients in our addressable market. Until we receive reimbursement, we expect that our revenues will continue to be fairly anemic and fluctuate quarter-to-quarter. With that said, however, we are right in front of several critical milestones, which Dane previously discussed, that we believe will be significant value creators, putting Helius in a much different place by the end of this year and even more so by the end of 2025.

Once we secure reimbursement by CMS as soon as October 1 of this year, we believe that revenues will begin to significantly increase and grow sequentially. We expect to further augment and accelerate revenue growth by adding third-party payer reimbursement and establishing a relationship with the VA to further penetrate the MS market in the U.S. Add to that, the potential authorization in stroke in the U.S. as soon as the second half of 2025 for which we will already have HCPCS codes and expect to have CMS reimbursement, we believe will allow us to immediately address the much larger stroke market and grow revenues at an even greater rate. With that, Justin, let’s open up the call for questions.

See also 14 Best High-Yield Dividend Stocks To Buy Now and Insiders Are Selling These 10 Retail Stocks.

Q&A Session

Operator: Thank you. [Operator Instructions] And our first question comes from Jonathan Aschoff from Roth MKM. Your line is now open.

Jonathan Aschoff: Thank you, guys. Given the broad buy-in for all the PoNS evaluations that are going on and the positive data you’ve shown, and it certainly looks like positive data, more of that’s coming. It kind of makes me focus on the key item of reimbursement. So once Medicare fully establishes the codes by October, what if anything, are any remaining possible reimbursement hurdles for a Medicare patient? And do you expect to encounter those if they exist?

Dane Andreeff: Yes, hi Jonathan, this is Dane. Thanks for your question. We don’t see too many hurdles. There is two things we’re to be doing. We do have the codes, the HCPCS codes right now. So they go effective April 1, and we’re able to begin negotiating with third-party payers, using those codes as well as submit claims on a case-by-case basis. All of this activity will provide further evidence for Medicare to establish pricing.

Jonathan Aschoff: Okay.

Dane Andreeff: And one other thing…

Jonathan Aschoff: I am sorry. No, continue.

Dane Andreeff: Yes. No, one of the things that we’ll be doing as well, we mentioned we’re going to be establishing a VA distributor and be able to be a supplier for PoNS therapy to the VA. There is four centers of excellence for MS. In the VA there is well over 250 hospitals, and we look forward to helping veterans with VA improve their daily activities using PoNS therapy.

Jonathan Aschoff: Okay. And so is the open-label stroke trial, the one that’s starting with the Florida Center, is that two arms or is it one arm?

Dane Andreeff: The open-label is a single-arm study with the same primary, which is gait and balance but also has the key secondary of the risk of falling and a durability effect, like the ERPT.

Jonathan Aschoff: [Indiscernible] Dane, my question is, will you have any cannibalism from the MUSC led trial, both of which you need for approval because a patient would rather go into a single-arm trial where they know they’re going to get treatment. Do you expect that where you have overlapping sites like the Florida center? [Indiscernible]

Dane Andreeff: We do not believe, though. Yes, we do not believe there will be cannibalization by any patient.

Jonathan Aschoff: Okay. So will the OpEx track over the quarters of 2024 in line with the drop we see in just reported in 4Q 2023. Is that kind of a new, much less OpEx plan for the time being?

Jeff Mathiesen: Yes, hi, Jonathan, I’ll take that. This is Jeff. So we typically have, as you can – if you track on a quarterly basis, first quarter is typically the highest quarter expense, right, because we have to have legal and audit fees and that type of thing go in. And you see that start to step down a little bit in the second quarter, but there’s still costs related to the annual meeting and those types of activities. And then it typically flattens out a little bit more in the fourth quarter. So, you’ll see that kind of overall trend in general. And beyond that, we don’t see significant cost changes or increases in the near future on a quarterly basis as we move forward in the year. As we start to ramp up revenues, there will be some costs, but those costs should be relatively modest when compared to the revenue growth that will come.

Jonathan Aschoff: Thank you very much guys, that’s all that I had.

Dane Andreeff: All right, thanks a lot. Appreciate it Jonathan.

Operator: And thank you. And our next question comes from Jeff Cohen from Ladenburg Thalmann & Company. Your line is now open.

Jeff Cohen: Great. Dane and Jeff how are you?

Dane Andreeff: Good Jeff how are you?

Jeff Mathiesen: Good morning Jeff.

Jeff Cohen: So, two questions from my end. Can you give us a sense on the Quebec order, deliveries and initiation with patients, do you expect that in the second quarter, third quarter, fourth quarter?

Jeff Mathiesen: Hey Jeff, I’ll take that. This is Jeff. Yes, so right now, the contract requires that we identify five sites, five different regions, so that process is going on. And we would expect that we will have those sites kind of coming under contract during the second quarter and then in the third quarter with deliveries following shortly thereafter. So there may be some activity here in the second quarter and more happening in the third quarter. But the idea is, initially, what was originally agreed to was extended to the end of September as far as having them all in place. And so that is something that when you’re dealing with these types of centers, it’s not a situation where you can walk in and within a week kind of have a relationship set up and the contract agreed to it becomes a process.

And we’ve been doing that. We’ve got – we’ve made some good progress. We’ve got some of those sites that we believe are close to being under contract and we’ll continue that process. So a long answer to your question, but it should play out here over the next couple of quarters.

Jeff Cohen: Okay. Got it. And then second for us, maybe for Dane, could you talk about how things may look toward the end of the year as far as FTEs and personnel on your end and number of centers, number of folks trade out. There just a sense of what’s going to exist commercially from the company by the end of the year?

Dane Andreeff: Hey Jeff, can you repeat that first part? I don’t think the Internet picked up that first part of your question.

Jeff Cohen: My apologies. Got it.

Dane Andreeff: Yes.

Jeff Cohen: Just trying to get a sense of how things look commercially as 2024 plays out as far as how you’re measuring yourself with personnel and number of centers, number of trained folks out there, et cetera?